Grufity logoGrufity logo

Repligen Corp Stock Research

RGEN

168.36USD-1.21(-0.71%)Market Closed

Market Summary

USD168.36-1.21
Market Closed
-0.71%

RGEN Alerts

RGEN Stock Price

RGEN RSI Chart

RGEN Valuation

Market Cap

9.4B

Price/Earnings (Trailing)

50.3

Price/Sales (Trailing)

11.67

EV/EBITDA

32.55

Price/Free Cashflow

107.21

RGEN Price/Sales (Trailing)

RGEN Profitability

EBT Margin

27.34%

Return on Equity

9.73%

Return on Assets

7.37%

Free Cashflow Yield

0.93%

RGEN Fundamentals

RGEN Revenue

Revenue (TTM)

801.5M

Revenue Y/Y

0.13%

Revenue Q/Q

-6.96%

RGEN Earnings

Earnings (TTM)

186.0M

Earnings Y/Y

67.4%

Earnings Q/Q

20.6%

Price Action

52 Week Range

137.21262.26
(Low)(High)

Last 7 days

5.1%

Last 30 days

-4.5%

Last 90 days

-0.6%

Trailing 12 Months

-10.5%

RGEN Financial Health

Current Ratio

2.47

RGEN Investor Care

Shares Dilution (1Y)

0.43%

Diluted EPS (TTM)

3.24

Peers (Alternatives to Repligen)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
40.8B
6.8B
0.60% 4.89%
32.54
5.96
8.37% 3.64%
36.7B
4.6B
17.13% -33.44%
-8.34
8.02
1.28% -677.95%
33.9B
3.9B
7.92% 11.43%
38.83
8.64
5.43% 13.46%
11.7B
1.1B
-0.96% -31.21%
44.48
10.41
8.77% 24.82%
MID-CAP
9.4B
801.5M
-4.54% -10.49%
50.3
11.67
19.54% 44.95%
SMALL-CAP
2.6B
128.3M
32.04% 27.25%
-8.35
20.44
-1.69% -73.40%
1.3B
185.3M
8.61% -36.38%
-6.31
6.82
20.06% 3.42%
462.5M
127.3M
6.80% -71.51%
-2.9
3.63
-12.28% -38.43%
420.1M
105.5M
6.82% -61.39%
-4.34
3.98
-4.55% -67.63%
329.9M
27.8M
-14.62% -56.98%
-2.49
11.87
54.62% -83.06%
272.5M
138.6M
-10.58% -79.92%
-8.11
1.97
32.30% -57.86%
176.7M
113.3M
54.41% -32.37%
-18.57
1.56
-4.68% -3204.17%
114.1M
72.0M
-6.71% -37.80%
-6.91
1.58
6.82% 39.11%
54.5M
54.1M
-13.17% -50.55%
504.68
1.01
21.80% -72.38%

Financials for Repligen

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue0.0%802801779734671
  S&GA Expenses0.5%216215209199184
  R&D Expenses4.8%44.0042.0041.0039.0034.00
Costs and Expenses-1.9%577588573543503
EBITDA7.5%271252248220-
EBITDA Margin7.5%0.34*0.31*0.30*0.30*-
Earnings Before Taxes9.0%219201195179154
EBT Margin9.0%0.27*0.25*0.25*0.24*-
Interest Expenses-69.2%1.004.006.009.0011.00
Net Income11.8%186166159146128
Net Income Margin11.8%0.23*0.21*0.20*0.20*-
Free Cahsflow37.8%87.0063.0045.0046.00-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets2.5%2,5252,4632,4452,3842,358
  Current Assets4.7%998953976945932
    Cash Equivalents-8.7%523573597585604
  Inventory-1.8%238243239214184
  Net PPE9.4%191174168148125
  Goodwill0.5%856851854859860
Liabilities-2.1%614627640617608
  Current Liabilities-1.6%404411424424375
Shareholder's Equity4.1%1,9111,8351,8051,7661,750
  Retained Earnings14.0%397349308258194
  Additional Paid-In Capital0.4%1,5471,5411,5341,5291,572
Shares Outstanding0.1%56.0056.0055.0055.0055.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations7.7%172160141133119
  Share Based Compensation-2.7%27.0028.0029.0029.0028.00
Cashflow From Investing-33.9%-233-174-249-240-221
Cashflow From Financing-3.9%-13.34-12.83-14.20-11.571.00

Risks for RGEN

What is the probability of a big loss on RGEN?

67.7%


Probability that Repligen stock will be more than 20% underwater in next one year

32.7%


Probability that Repligen stock will be more than 30% underwater in next one year.

19.2%


Probability that Repligen stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does RGEN drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Repligen was unfortunately bought at previous high price.

Drawdowns

Returns for RGEN

Cumulative Returns on RGEN

37.3%


10-Year Cumulative Returns

29.9%


7-Year Cumulative Returns

36%


5-Year Cumulative Returns

20.4%


3-Year Cumulative Returns

What are the long-term rolling returns for RGEN?

FIve years rolling returns for Repligen.

Annualized Returns

Which funds bought or sold RGEN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-24
PALISADE CAPITAL MANAGEMENT, LP
reduced
-2.00
-4,975,780
38,957,200
1.05%
2023-03-23
MetLife Investment Management, LLC
reduced
-2.01
-738,731
5,782,610
0.05%
2023-03-17
American Portfolios Advisors
added
0.17
29,136
218,170
0.01%
2023-03-15
B. Riley Wealth Advisors, Inc.
reduced
-2.14
-59,136
448,864
0.01%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-66.97
-15,233,900
6,495,070
0.01%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-0.12
-15,000
145,000
-%
2023-03-06
NORTH STAR ASSET MANAGEMENT INC
added
3.01
-1,073,480
14,743,500
0.92%
2023-03-06
Rockefeller Capital Management L.P.
new
-
3,000
3,000
-%
2023-03-02
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA
new
-
5,757
5,757
-%
2023-02-28
Voya Investment Management LLC
reduced
-0.23
-378,569
3,518,430
-%

1–10 of 45

Latest Funds Activity

Are funds buying RGEN calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own RGEN
No. of Funds

Repligen News

Nasdaq

Surprising Analyst 12-Month Target For IJK.

Nasdaq,
47 hours ago

Simply Wall St

Best Stocks

Yahoo Finance

Zacks Investment Research

Schedule 13G FIlings of Repligen

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 15, 2023
eddleman roy t
4.87%
2,705,689
SC 13G/A
Feb 14, 2023
price t rowe associates inc /md/
9.1%
5,070,657
SC 13G/A
Feb 09, 2023
vanguard group inc
9.37%
5,205,155
SC 13G/A
Jan 23, 2023
blackrock inc.
11.0%
6,123,594
SC 13G/A
Sep 08, 2022
blackrock inc.
10.2%
5,686,997
SC 13G
Feb 14, 2022
price t rowe associates inc /md/
5.5%
3,042,655
SC 13G
Feb 10, 2022
vanguard group inc
8.89%
4,912,769
SC 13G/A
Feb 01, 2022
blackrock inc.
9.4%
5,189,189
SC 13G/A
Feb 10, 2021
vanguard group inc
8.12%
4,410,742
SC 13G/A
Feb 05, 2021
eddleman roy t
6.65%
3,500,000
SC 13G/A

RGEN Fair Value

Repligen fair value in different scenarios

The table shows the Fair Value estimates for Repligen for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

96.61

-42.62%

125.13

-25.68%

240.22

42.68%

394.48

134.31%

633.95

276.54%
Current Inflation

88.66

-47.34%

112.97

-32.90%

211.21

25.45%

341.26

102.70%

542.87

222.45%
Very High Inflation

78.87

-53.15%

98.29

-41.62%

177.13

5.21%

279.73

66.15%

438.53

160.47%

Historical Repligen Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Repligen

View All Filings
Date Filed Form Type Document
Mar 24, 2023
PRE 14A
PRE 14A
Mar 06, 2023
4
Insider Trading
Mar 06, 2023
4
Insider Trading
Mar 06, 2023
4
Insider Trading
Mar 06, 2023
4
Insider Trading
Mar 06, 2023
4
Insider Trading
Mar 02, 2023
4
Insider Trading
Mar 02, 2023
4
Insider Trading
Mar 01, 2023
4
Insider Trading
Mar 01, 2023
4
Insider Trading

Latest Insider Trading transactions for RGEN

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-03
KURIYEL RALF
sold (taxes)
-234,436
188
-1,247
senior vp, r&d
2023-03-03
Snodgres Jon
sold (taxes)
-690,712
188
-3,674
chief financial officer
2023-03-03
Bylund James
sold (taxes)
-39,480
188
-210
chief operating officer
2023-03-03
Hunt Anthony
acquired
-
-
18,584
chief executive officer
2023-03-03
Snodgres Jon
acquired
-
-
8,795
chief financial officer
2023-03-03
Gebski Christine
sold (taxes)
-23,688
188
-126
see remarks
2023-03-03
Bylund James
acquired
-
-
625
chief operating officer
2023-03-03
Gebski Christine
acquired
-
-
375
see remarks
2023-03-03
KURIYEL RALF
acquired
-
-
3,591
senior vp, r&d
2023-03-03
Hunt Anthony
sold (taxes)
-1,549,870
188
-8,244
chief executive officer

1–10 of 50

Tony J. Hunt
1850
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

RGEN Income Statement

2022-12-31
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenue:   
Revenue$ 801,536$ 670,534$ 366,260
Costs and operating expenses:   
Cost of product revenue345,830279,280156,634
Research and development43,93634,27420,182
Selling, general and administrative215,829183,866119,621
Contingent consideration(28,729)5,8650
Total costs and operating expenses576,866503,285296,437
Income from operations224,670167,24969,823
Other (expenses) income:   
Investment income6,9781761,741
Interest expense(1,162)(11,278)(10,768)
Amortization of debt issuance costs1,8151,4361,365
Other expenses(9,531)(1,168)(214)
Other expenses, net(5,530)(13,706)(10,606)
Income before income taxes219,140153,54359,217
Income tax provision (benefit)33,18125,252(709)
Net income$ 185,959$ 128,291$ 59,926
Earnings per share:   
Basic$ 3.35$ 2.33$ 1.14
Diluted$ 3.24$ 2.24$ 1.11
Weighted average common shares outstanding:   
Basic55,46055,01552,554
Diluted57,45557,26453,892
Net income$ 185,959$ 128,291$ 59,926
Other comprehensive income (loss):   
Foreign currency translation adjustment(17,508)(18,971)17,112
Comprehensive income168,451109,32077,038
Products   
Revenue:   
Revenue801,183670,319[1]366,136[2]
Royalty and Other Revenue   
Revenue:   
Revenue$ 353$ 215$ 124
[1]2021 revenue for filtration products includes revenue related to Polymem from July 1, 2021, as well as BioFlex and NTM from December 16, 2021 through December 31, 2021. 2021 revenue for proteins products includes revenue related to Avitide from September 20, 2021 through December 31, 2021.
[2]2020 revenue for filtration products includes revenue related to EMT from July 13, 2020, NMS from October 20, 2020, and ARTeSYN from December 3, 2020 through December 31, 2020.

RGEN Balance Sheet

2022-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 523,458$ 603,814
Marketable securities held to maturity100,2990
Accounts receivable, net of reserves of $1,365 and $1,417 at December 31, 2022 and December 31, 2021, respectively116,247117,420
Inventories, net238,277184,494
Prepaid expenses and other current assets19,83725,949
Total current assets998,118931,677
Property, plant and equipment, net190,673124,964
Intangible assets, net353,676337,274
Goodwill855,513860,362
Deferred tax assets8401,903
Operating lease right of use assets125,023101,559
Other noncurrent assets815615
Total noncurrent assets1,526,5401,426,677
Total assets2,524,6582,358,354
Current liabilities:  
Accounts payable27,55436,203
Operating lease liability6,9578,303
Current contingent consideration13,9500
Accrued liabilities71,12075,498
Convertible Senior Notes, net284,615255,258
Total current liabilities404,196375,262
Deferred tax liabilities23,00033,480
Noncurrent operating lease liability131,389102,492
Noncurrent contingent consideration51,55994,238
Other noncurrent liabilities3,8142,815
Total noncurrent liabilities209,762233,025
Total liabilities613,958608,287
Commitments and contingencies (Note 12)
Stockholders' equity:  
Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding00
Common stock, $0.01 par value; 80,000,000 shares authorized; 55,557,698 shares at December 31, 2022 and 55,321,457 shares at December 31, 2021 issued and outstanding556553
Additional paid-in capital1,547,2661,572,340
Accumulated other comprehensive loss(34,394)(16,886)
Accumulated earnings397,272194,060
Total stockholders' equity1,910,7001,750,067
Total liabilities and stockholders' equity$ 2,524,658$ 2,358,354